Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

38.17 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
27 28 Next >
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?
Crispr and Vertex are working toward the first submissions for a CRISPR-based product. 
Via Investor's Business Daily
Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease
The estimated cost of Alzheimer's disease and related dementia (ADRD) care in 2021 was $355 billion. Investing in the top companies that are making steady progress toward developing a treatment for... 
Via Talk Markets
FDA Approves Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
From Genentech
Via Business Wire
Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data
Although Gilead Sciences produced meaningful results regarding a lung cancer drug test, the competitive shortfall hurt GILD stock. 
Via InvestorPlace
Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche
Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. 
Via Investor's Business Daily
Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum 
Via MarketBeat
OTC Market Group’s Most Active List In November: A Dive Into The Names Experiencing Volume Changes
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ)... 
Via TheNewswire.com
Topics ETFs Economy Stocks
Exposures Interest Rates US Equities
OTC Market Group's Most Active List In November: A Dive Into The Names Experiencing Volume Changes
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022. 
Via Benzinga
Roche Presents New Data Demonstrating Potential Benefit Of Two Lymphoma Candidates
Via Benzinga
Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A
From Spark Therapeutics, Inc.
Via GlobeNewswire
Genentech Presents New Data Demonstrating the Potential of Glofitamab and Mosunetuzumab as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma
From Genentech
Via Business Wire
Broadcom-Vmware Deal Draws European Regulatory Attention, Rivian Pauses Mercedes-Partnered EV Van Plans For Europe, Credit Suisse Issued Loan On Suspicious Bills: Top Stories Monday, Dec. 12
Reuters Broadcom's Vmware Draws More Regulatory Attention, This Time From EU 
Via Benzinga
After 16 Years, Roche's Pharma Division Head Decides To Step Down
Via Benzinga
Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022
From Genentech
Via Business Wire
Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From Birth
From Genentech
Via Business Wire
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study  
Via Benzinga
3 Hot Stocks That Could Live Up to Their Lofty Valuations
These companies have long runways of growth ahead 
Via The Motley Fool
Replimune Shares Surge After Early Data From Pretreated Melanoma Patients
Via Benzinga
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. 
Via Benzinga
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 1, 2022 – USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug... 
Via FinancialNewsMedia
Exposures Product Safety
Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges
Gilead and Arcus notched another win for their cancer program on Monday. GILD stock briefly hit a four-year high as RCUS stock gapped higher. 
Via Investor's Business Daily
This Congressman Just Purchased 2 Stocks Which Consistently Increase Dividends
Congressman Dwight Evans (D-PA) has represented Pennsylvania's Third Congressional District since 2019, and has made over 70 trades in the past three years. His top two traded investments are Intel... 
Via Benzinga
Daily Stock Analysis: Roche Holding
By my dogcatcher ideal, this is not a good time to buy Roche Holding AG shares based on their dividends for the coming year 2022-23. 
Via Talk Markets
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
Neurodegenerative disorders could mean big bucks for some biotechs. 
Via Investor's Business Daily
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
Via Benzinga
FDA Gives Emergency Use Nod To Roche's Monkeypox Test
Via Benzinga
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage
Via Benzinga
Roche Inks Second Drug Discovery Deal With Jnana Therapeutics
Via Benzinga
The OTCQB Venture Market Records 4 Months Of Consecutive Volume Increases In OTC Market Group’s Most-Active List In October
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 8.13% in October — its second-largest monthly increase in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ) and the SPDR Dow Jones... 
Via TheNewswire.com
Topics ETFs Stocks
Exposures US Equities
FDA Grants Conditional Approval To First Antibody Drug Conjugate From ImmunoGen For Pretreated Ovarian Cancer
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
27 28 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.